Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease, but the company could see pushback from the government following studies.
Overall, results from the phase III Valor trial testing Lyme disease vaccine PF-07307405 “strengthen confidence” in the candidate, according to partners Pfizer Inc. and Valneva SE, with the big pharma ...
The annual tick report shows Lone Star ticks have established populations along Connecticut's shoreline, raising the risk of ...
Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more ...
Danone is scooping up the maker of plant-based food powders and meal-replacement drinks to bolster its nutrition portfolio. Toyota to Invest $1 Billion in Kentucky, Indiana Operations The company will ...
If approved by regulators, it could become the only Lyme disease vaccine available for people — although it would not be the first.
Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until the stock exceeds $32. A closing-price condition could result in payment ...
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above -- The investigational vaccine candidate was well tolerated ...
A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed the results from a phase 3 trial. If approved by regulators, it would be ...
Pfizer wants to fill a 20-year void in human Lyme disease vaccines, but must win over regulators under a vaccine-skeptical administration ...
California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in near-term payments for rights to a T-cell engager (TCE) for autoimmune ...
As part of the settlement, Moderna will pay Arbutus and Genevant $950 million upfront in July 2026 ("Noncontingent Settlement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results